The main principles of managing patients with Graves’ disease in clinical practice

BACKGROUND: Graves’ disease (GD) is a common cause of persistent thyrotoxicosis. In regions with adequate iodine intake, the incidence is 20–30 cases per 100,000 people. Modern treatment of GD includes antithyroid drugs, radioactive iodine therapy (RAI), and thyroidectomy. The choice of treatment strategy is based on the severity of thyrotoxicosis, the frequency of potential side effects, the availability of treatment options, and the likelihood of achieving sustained remission. Previous studies have demonstrated differences in approaches to diagnosis, treatment, and follow-up between countries and individual specialists.

AIM: To conduct a survey on the current clinical practice of treating Graves’ disease in Russia.

MATERIALS AND METHODS: An online survey was conducted among physicians in 2022-2023. The questions covered the principles of diagnosis, treatment, and dynamic observation of adult patients with Graves’ disease.

RESULTS: The study involved 104 physicians of various specialties who treat patients with Graves’ disease. Approximately 99% of respondents chose the determination of thyroid-stimulating hormone receptor antibodies (TSHR-ab) to clarify the etiology of thyrotoxicosis, while only 60.6% of them chose thyroid scintigraphy. As the first-line treatment method, antithyroid drug therapy is chosen by 88.5%, while 13.5% of physicians use radioactive iodine therapy (RAI), and less than 1% of respondents refer patients to thyroidectomy. Thiamazole is most commonly used (99%), while propylthiouracil (PTU) is used in cases of allergy to thiamazole or during the first trimester of pregnancy. The «block-replace» scheme is preferred over the  «block» scheme, with 72.1% compared to 28.8%, respectively. The majority of physicians (95.2%) initiate therapy with moderate doses of thiamazole (20–30 mg) and PTU (200–300 mg). Most physicians conduct dynamic monitoring of liver transaminase levels (57.7%) and complete blood count (78.8%). Conservative therapy is prescribed for a period of 12–18 months (88.5%) or up to 24 months (10.6%). Before discontinuing antithyroid drug therapy, 89.4% of respondents monitor thyroid hormone levels, 82.7% monitor TSHR-Ab levels, and 47.1% perform thyroid ultrasound. Repeat courses of conservative therapy are prescribed for up to 61.5% of respondents. Approximately 63.5% of surveyed physicians reported difficulties in referring patients for radical treatment due to a limited number of specialized institutions. Physicians cited patient unwillingness and the need to postpone pregnancy (81.6% and 24.3% respectively) as the main inhibitory factors for RAI. Thyroidectomy was associated with patient unwillingness (69.2%), as well as physician fear of laryngeal paralysis (48.1%) and postoperative hypoparathyroidism (49%).

CONCLUSION: The results of the study demonstrated that physicians in their practice generally adhere to international recommendations for the treatment of Graves’ disease.

1. Ross DS, Burch HB, Cooper DS, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis [published correction appears in Thyroid. 2017;27(11):1462]. Thyroid. 2016;26(10):1343-1421. doi:https://doi.org/10.1089/thy.2016.0229

2.

3. Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. ClinEndocrinol (Oxf ). 2013. doi: https://doi.org/10.1111/cen.12060

4.

5. McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ ethnicity in US military personnel. JAMA. 2014;311(15):1563-1565. doi:https://doi.org/10.1001/jama.2013.285606

6.

7. Brix TH, Kyvik KO, Christensen K, Hegedüs L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86(2):930-934. doi:https://doi.org/10.1210/jcem.86.2.7242

8.

9. Strieder TG, Prummel MF, Tijssen JG, et al. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf ). 2003;59(3):396-401. doi: https://doi.org/10.1046/j.1365-2265.2003.01862.x

10.

11. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229(5):415-420. doi:https://doi.org/10.1111/j.1365-2796.1991.tb00368.x

12.

13. Brix TH, Hansen PS, Kyvik KO, Hegedüs L. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000;160(5):661-666. doi: https://doi.org/10.1001/archinte.160.5.661

14.

15. Bartalena L. Diagnosis and management of Graves disease: a global overview. NatRevEndocrinol. 2013;9(12):724-734. doi: https://doi.org/10.1038/nrendo.2013.193

16.

17. Grebe SK, Kahaly GJ. Laboratory testing in hyperthyroidism. Am J Med. 2012;125(9):S2. doi: https://doi.org/10.1016/j.amjmed.2012.05.013

18.

19. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. ClinEndocrinol (Oxf ). 2016;84(1):115-120. doi: https://doi.org/10.1111/cen.12688

20.

21. Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med. 2016;375(16):1552-1565. doi:https://doi.org/10.1056/NEJMra1510030

22.

23. Goichot B, Bouée S, Castello-Bridoux C, Caron P. Survey of Clinical Practice Patterns in the Management of 992 Hyperthyroid Patients in France. EurThyroid J. 2017;6(3):152-159. doi: https://doi.org/10.1159/000453260

24.

25. Kahaly GJ, Bartalena L, Hegedüs L, et al. European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186. doi:https://doi.org/10.1159/000490384

26.

27. Koren S, Shteinshnaider M, Or K, et al. A 2017 Survey of the clinical practice patterns in the management of relapsing Graves disease. EndocrPract. 2019;25(1):55-61. doi: https://doi.org/10.4158/EP-2018-0386

28.

29. Hookham J, Collins EE, Allahabadia A, Balasubramanian SP. Variation in the use of definitive treatment options in the management of Graves’ disease: a UK clinician survey. Postgrad Med J. 2017;93(1098):198-204. doi: https://doi.org/10.1136/postgradmedj-2016-134187

30.

31. Sriphrapradang C. Diagnosis and Management of Graves’ Disease in Thailand: A Survey of Current Practice. J Thyroid Res. 2020;2020:8175712. doi: https://doi.org/0.1155/2020/8175712

32.

33. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J ClinEndocrinolMetab. 2012;97(12):4549-4558. doi: https://doi.org/10.1210/jc.2012-2802

34.

35. Sriphrapradang C. Diagnosis and Management of Graves’ Disease in Thailand: A Survey of Current Practice. J Thyroid Res. 2020;2020:8175712. doi:https://doi.org/10.1155/2020/8175712

36.

37. Wang X, Teng X, Li C, et al. A Chinese survey on clinical practice in hyperthyroidism management: comparison with recent studies and guidelines. Endocr Connect. 2021;10(9):1091-1100. doi: https://doi.org/10.1530/EC-21-0340

38.

39. Thewjitcharoen Y, Karndumri K, Chatchomchuan W, et al. Practice patterns and outcomes in the management of Thai patients with Graves’ disease. Thyroid Res. 2021;14(1):5. doi: https://doi.org/10.1186/s13044-021-00097-y

40.

41. Negro R, Attanasio R, Grimaldi F, et al.AME (Associazione Medici Endocrinologi) and AACE (American Association of Clinical Endocrinologists) Italian Chapter. A 2015 Italian Survey of Clinical Practice Patterns in the Management of Graves’ Disease: Comparison with European and North American Surveys. EurThyroid J. 2016;5(2):112-119. doi: https://doi.org/10.1159/000444482

42.

43. Трошина Е.А. и др. Клинические рекомендации по диагностике и лечению тиреотоксикоза с диффузным зобом (болезнь Грейвса), узловым/многоузловым зобом //М.: РАЭ. —2021.

44.

45. Wiersinga WM. Graves’ Disease: Can It Be Cured? EndocrinolMetab (Seoul). 2019;34(1):29-38. doi: https://doi.org/10.3803/EnM.2019.34.1.29

46.

47. Фадеев В.В., Абрамова Н.А., Прокофьев С.А., и др. Антитела к рецептору ТТГ в дифференциальной диагностике токсического зоба // Проблемы эндокринологии. — 2005. — Т.51. — №4. — С. 10–18. doi: https://doi.org/10.14341/probl200551410-18